

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/532746		ATTY. DOCKET NO.: C1037.70035US1			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				FILING DATE: September 9, 2005		CONFIRMATION NO.: 2683			
				APPLICANT: Navneet K. Ahluwalia et al.					
				GROUP ART UNIT: 1648		EXAMINER: E.M. Le			
Sheet	1	of	1						

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C4.	[No Author Listed] "Hepatitis C: Safety and Efficacy of CPG 10101," Hepatitis Journal Review. Hepatitis C Support Project. 2007 Dec 10;4(22):1-3.	
	C5.	[No Author Listed] "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy," Press Release, Wellesley, MA, 2007 Jan 22/PRNewswire-FirstCall—Coley Pharmaceutical Group, Inc.	
	C6.	DEUTSCH et al., Old and emerging therapies in chronic hepatitis C: an update. J Viral Hepat. 2008 Jan;15(1):2-11.	
	C7.	JACOBSON et al., "CPG10101 HCV Toll-Receptor 9 Antagonist Phase II Study Results," 57 th Annual Meeting of the American Association for the Study of Liver Diseases. October 27-31, 2006. Boston, MA. 11 pages.	
	C8.	MCHUTCHISON et al., "Early Viral Response to New HCV Drug CPG 10101 Toll-Receptor Antagonist, in Combination with Pegylated Interferon and/or Ribavirin, in Chronic HCV Genotype 1 Infected Patients with Prior Relapse Response," 41 st Meeting of the European Association for the Study of Liver Diseases. April 26-30, 2006. Vienna, Austria. 8 pages.	
	C9.	MCHUTCHISON et al., "Phase 1B Study Shows Toll-Like Receptor 9 Agonist CPG 10101 Decreases HCV RNA in Patients with Chronic Hepatitis C," 58 th Annual Meeting of the American Association for the Study of Liver Diseases. November 2-6, 2007. Boston, MA. 2 pages.	
	C10.	MCHUTCHISON et al., "Early Viral Response to CPG 10101 in Combination with Pegylated Interferon and/or Ribavirin, in Chronic HCV Genotype 1 Infected Patients with Prior Relapse Response," 2006 European Association for the Study of the Liver (EASL) April 26-30, 2006. Abstract. 1 page.	

EXAMINER: /Emily Le/	DATE CONSIDERED: 01/14/2009
-------------------------	--------------------------------

* EXAMINER: Initial if reference considered, whether or notation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 128T06163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. 120.]

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.L./